Aardvark Therapeutics reviews ARD-101 and ARD-201 programs at investor webinar; no new data disclosed

Aardvark Therapeutics, Inc.

Filed presentation lacks specific clinical results or financial figures.
Webinar covered ARD-101 and ARD-201 programs and ObesityWeek 2025 presentations.
Materiality is limited as filing is a procedural update without substantive new information.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.